These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 26372797)

  • 61. Current update on eosinophilic lung diseases and anti-IL-5 treatment.
    Samitas K; Rådinger M; Bossios A
    Recent Pat Antiinfect Drug Discov; 2011 Sep; 6(3):189-205. PubMed ID: 21824072
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of Monoclonal Antibodies for Treatment of Uncontrolled Eosinophilic Asthma.
    Koski RR; Grzegorczyk KM
    J Pharm Pract; 2020 Aug; 33(4):513-522. PubMed ID: 31046541
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Mepolizumab in eosinophilic disorders.
    Abonia JP; Putnam PE
    Expert Rev Clin Immunol; 2011 Jul; 7(4):411-7. PubMed ID: 21790283
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling of Weight-Based Intravenous Reslizumab Dosing.
    Passarell J; Jaworowicz D; Ludwig E; Rabinovich-Guilatt L; Cox DS; Levi M; Garin M; Fiedler-Kelly J; Bond M
    J Clin Pharmacol; 2020 Aug; 60(8):1039-1050. PubMed ID: 32333684
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study.
    Bjermer L; Lemiere C; Maspero J; Weiss S; Zangrilli J; Germinaro M
    Chest; 2016 Oct; 150(4):789-798. PubMed ID: 27056586
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy of Reslizumab Treatment in Exacerbation-Prone Patients with Severe Eosinophilic Asthma.
    Wechsler ME; Hickey L; Garin M; Chauhan A
    J Allergy Clin Immunol Pract; 2020; 8(10):3434-3442.e4. PubMed ID: 32562877
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Anti-interleukin-5 antibody therapy in asthma and allergies.
    Corren J
    Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):565-70. PubMed ID: 21971335
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Immunological and hematological effects of IL-5(Rα)-targeted therapy: An overview.
    Hassani M; Koenderman L
    Allergy; 2018 Oct; 73(10):1979-1988. PubMed ID: 29611207
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Impact of reslizumab on the course of chronic rhinosinusitis in patients with eosinophilic asthma].
    Boiko NV; Lodochkina OE; Kit MM; Kuleshova VG; Nedashkovskaya NG
    Vestn Otorinolaringol; 2021; 86(2):43-48. PubMed ID: 33929151
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
    Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma.
    Dávila González I; Moreno Benítez F; Quirce S
    J Investig Allergol Clin Immunol; 2019 Apr; 29(2):84-93. PubMed ID: 31017107
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis.
    Nagase H; Ueki S; Fujieda S
    Allergol Int; 2020 Apr; 69(2):178-186. PubMed ID: 32139163
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Anti-interleukin 5 Therapy for Eosinophilic Asthma: a Meta-analysis of Randomized Clinical Trials.
    Wang FP; Xiong XF; Liu T; Li SY; Cheng DY; Mao H
    Clin Rev Allergy Immunol; 2018 Apr; 54(2):318-330. PubMed ID: 27677499
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The spectrum of therapeutic activity of mepolizumab.
    Cavaliere C; Frati F; Ridolo E; Greco A; de Vincentiis M; Masieri S; Makri E; Incorvaia C
    Expert Rev Clin Immunol; 2019 Sep; 15(9):959-967. PubMed ID: 31424304
    [No Abstract]   [Full Text] [Related]  

  • 75. Interleukin-4/interleukin-13 versus interleukin-5: a comparison of molecular targets in biologic therapy for the treatment of severe asthma.
    Wu AY; Sur S; Grant JA; Tripple JW
    Curr Opin Allergy Clin Immunol; 2019 Feb; 19(1):30-37. PubMed ID: 30407206
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Role of biologics in severe eosinophilic asthma - focus on reslizumab.
    Pelaia G; Vatrella A; Busceti MT; Gallelli L; Preianò M; Lombardo N; Terracciano R; Maselli R
    Ther Clin Risk Manag; 2016; 12():1075-82. PubMed ID: 27445482
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Exacerbations of Severe Asthma While on Anti-IL-5 Biologics.
    Bhalla A; Zhao N; Rivas DD; Ho T; Perez de Llano L; Mukherjee M; Nair P
    J Investig Allergol Clin Immunol; 2020; 30(5):307-316. PubMed ID: 32573459
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena.
    Mukherjee M; Forero DF; Tran S; Boulay ME; Bertrand M; Bhalla A; Cherukat J; Al-Hayyan H; Ayoub A; Revill SD; Javkar T; Radford K; Kjarsgaard M; Huang C; Dvorkin-Gheva A; Ask K; Olivenstein R; Dendukuri N; Lemiere C; Boulet LP; Martin JG; Nair P
    Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32444405
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis.
    Edris A; De Feyter S; Maes T; Joos G; Lahousse L
    Respir Res; 2019 Aug; 20(1):179. PubMed ID: 31395084
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial.
    Spergel JM; Rothenberg ME; Collins MH; Furuta GT; Markowitz JE; Fuchs G; O'Gorman MA; Abonia JP; Young J; Henkel T; Wilkins HJ; Liacouras CA
    J Allergy Clin Immunol; 2012 Feb; 129(2):456-63, 463.e1-3. PubMed ID: 22206777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.